Does Pharma Fund the Pipers? - Scottish Intercollegiate Guidelines Network (SIGN) Guidelines 90 - Diagnosis and Management of Head and Neck Cancer, October 2006

Clinical Oncology

Volumn 20, Issue 9, 2008, Pages 661-663

  Wilson, J A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DRUG MARKETING; DRUG RESPONSE; DYSPHONIA; EDITORIAL; ENDOSCOPY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HOARSENESS; HUMAN; LARYNGOSCOPY; MEDICAL LITERATURE; MONOTHERAPY; PATIENT CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RADIOSENSITIVITY; SIDE EFFECT; SUDDEN DEATH; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY; UNITED KINGDOM;

COMBINED MODALITY THERAPY; DECISION MAKING; EVIDENCE-BASED MEDICINE; HEAD AND NECK NEOPLASMS; HUMANS; PRACTICE GUIDELINES AS TOPIC; SCOTLAND;

EID: 52749093810     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.03.013     Document Type: Editorial

References (22)

1. In: Wilson J.A. (Ed). Effective head and neck cancer management: consensus document (2002), British Association of Otorhinolaryngologists Head and Neck Surgeons, London
2. Fakhry C.X., Westra W.H., Li S., et al. Improved survival of patients with human papilloma virus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100 (2008) 261-269
3. McKie C, Ahmad UA, Fellows S, et al. The 2-week rule for suspected head and neck cancer in the United Kingdom: referral patterns, diagnostic efficacy of the guidelines and compliance. Oral Oncol 2008 [Epub ahead of print].
4. Morton R.P., Hay K.D., and Macann A. On completion of curative treatment of head and neck cancer: why follow up?. Curr Opin Otolaryngol Head Neck Surg 12 (2004) 142-146
5. Ritoe S.C., de Vegt F., Scheike I.M., et al. Effect of routine follow-up after treatment for laryngeal cancer on life expectancy and mortality: results of a Markov model analysis. Cancer 109 (2007) 239-247
6. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368 (2006) 843-854
7. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
8. Winquist E., Oliver T., and Gilbert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta analysis. Head Neck 29 (2007) 38-46
9. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell cancer of the head and neck. N Engl J Med 354 (2006) 567-578
10. Parsons J.T., Mendenhall W.M., Stringer S.P., et al. Squamous cell carcinoma of the oropharynx. Surgery, radiation therapy or both. Cancer 94 (2002) 2967-2980
11. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1690
12. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
13. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006;116(Suppl 111):1-13.
14. Coombes R. Cancer drugs: swallowing big pharma's line?. Br Med J 334 (2007) 1034-1035
15. Peppercorn J., Blood E., Winer E., and Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 109 (2007) 1239-1246
16. www.destinationaccess.com
17. Sturgis E.M., and Cinciripini P.M. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?. Cancer 110 (2007) 1429-1435
18. Merck. Investor relations information. Merck KGaA to announce European colorectal cancer study data of Erbitux™ (Cetuximab) at ASCO; 27 May 2003. Available from: www.Investors.merck.de
19. Richey L.M., Shores C.G., George J., et al. The effectiveness of salvage surgery after the failure of primary concomitant chemoradiation in head and neck cancer. Otolaryngol Head Neck Surg 136 (2007) 98-103
20. Tsou Y.-A., Lin M.-H., Hua C.-H., et al. Survival outcome by early chemoradiation therapy salvage or early surgical salvage for the treatment of hypopharyngeal cancer. Otolaryngol Head Neck Surg 137 (2007) 711-716
21. Robbins K.T. Selecting from the menu of treatment options for locally advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 131 (2005) 819
22. In: Maran A.G.D., Gaze M., and Wilson J.A. (Eds). Stell and Maran's head and neck surgery. 3rd edn (1993), Butterworth Heinemann, Oxford [chapter 2]